REG - Immupharma PLC - ImmuPharma proves unique Mechanism of Action-P140

ImmuPharmaAnnouncement

13/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250313:nRSM4624Aa&default-theme=true

RNS Number : 4624A  Immupharma PLC  13 March 2025

 
13 March 2025

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

 

ImmuPharma proves unique Mechanism of Action of P140

 

ImmuPharma PLC (LSE:IMM), a leading specialist in peptide based drug discovery
and development, announces a significant milestone in evidencing the unique
mechanism of action ("MOA") of its P140 autoimmune technology platform.

 

Importantly, these new discoveries announced today, in respect to the MOA of
P140, highlight that:

 

·      P140 has a unique MOA: The results provide direct evidence for
the first time of a major key hypothesis of the unique MOA of P140.

 

·      P140 is non-immunosuppressive: Unlike the most advanced therapies
currently available for the treatment of autoimmune diseases, these findings
indicate that P140 does not reduce or block the body's ability to mount a
specific immune response.

 

·      P140 is effective and safe: These findings confirm P140's
potential as a safe and effective treatment for patients suffering from
systemic lupus erythematosus (SLE).

 

These discoveries result from a new preclinical study designed by ImmuPharma
Biotech's team and conducted at a world leading Laboratory in the USA. While
detailed data will be released in due course, these findings allow ImmuPharma
to further expand its intellectual property portfolio, with additional new
patents, strengthening the commercial viability of the P140 technology
platform.

 

Relevant therapy markets in this area are forecast to reach global sales of
c.$360 billion by 2030. There have been 11 relevant therapy product licensing
deals averaging $1bn total deal value in last 2 years. (UBS Investment Banking
Reports).

 

Commenting on this announcement, Tim McCarthy, CEO of ImmuPharma, said:

"These stunning results clearly demonstrate the unique MOA of P140 and this
data adds significantly to our ongoing discussions with potential partners and
our objective to secure the optimum deal(s) for our shareholders."

 

Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma
Biotech, said:

"These results are extremely compelling. Not only do they validate our MOA,
they also indicate that P140 has the possibility to become a central treatment
for a number of autoimmune diseases. Patients can be very hopeful, I certainly
am!"

 

 

Ends

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550 (about%3Ablank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140, is a unique non-immunosuppressive
peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP
(Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models
suggest therapeutic activity for many other autoimmune diseases.

 

 

About Lupus (Systemic Lupus Erythematosus / SLE)

 

Lupus is a chronic inflammatory disease which is thought to affect some 16
million individuals worldwide. The current standard of care still consists of
steroid and anti-malarial therapies which have side-effects and poor response
in many patients. Recently more targeted monoclonal therapies are
GlaxoSmithKline's Benlysta and more recently, AstraZeneca's Saphnelo. There
still exists a high unmet medical need for a drug that has a strong efficacy
and safety profile.

 

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESFFFELVVIFLIE